Miami Cancer Institute 2020 Philanthropy Impact Report
Future of Cancer Care Since opening its doors in 2017, Miami Cancer Institute has been providing world-renowned cancer treatment to over 1,000 patients daily. Through philanthropic support, we continue to bring the best of the world’s cancer research and treatment to South Florida. Having assembled over 110 of the world’s leading cancer physicians and researchers, Miami Cancer Institute is bringing best-in-class clinical trials to its patients and the field of cancer with the most exciting treatments possible. With the addition of Dr. Manmeet Ahluwalia, Chief of Medical Oncology, Chief Scientific Officer & Deputy Director, novel trials using the latest technology to help understand the genetic make-up of tumors and predict the evolution of cancers are within our reach. Coupled with the most exciting targeted drugs and immunotherapies to fight them, we are leading the fight against this deadly disease. Dr. Manmeet Ahluwalia
Philanthropy helps advance life-saving translational research, enabling Miami Cancer Institute to continue delivering acclaimed nonclinical patient programs and expand access to the most innovative cancer protocols available.
• Our collaboration with Florida International University and the Herbert Wertheim College of Medicine positions us to influence cancer care far beyond our region. Our most recent partnership involves a federally funded grant that includes the University of Antioquia in Colombia and will strengthen institutional capacity to conduct cancer research in developing and underserved countries. • Promise to Care Study: Breast cancer is the most common malignancy in women, with an estimated 325,010 new cases in 2020. When diagnosed at an early stage, it is one of the most curable cancers, with a survival of 90% and higher. Unfortunately, many women who do not have access to early detection and care ultimately end up being diagnosed at a later stage with a much lower survival rate. This study will provide women from West Palm Beach to Monroe County with equal access to contemporary cancer treatment to prove that underserved patients who are diagnosed at an earlier stage and receive contemporary treatment will have similar outcomes to those published when given equal access to care. IMPACT REPORT 14
